Brought to you by 
Questcor gets rights to Novartis' Synacthen
21 Jun 2016
Executive Summary
Questcor Pharmaceuticals Inc. (inflammation, neurology, and autoimmune disorders) has licensed exclusive rights to Novartis Pharma AG’s Synacthen (tetracosactide) and Synacthen Depot. The transaction includes licenses to the US and over three dozen ex-European countries.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Questcor gets rights to Novartis' Synacthen
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice